Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
April 08, 2022 09:15 ET
|
Medicenna Therapeutics Corp.
-- Anti-PD1-IL-2 BiSKIT (Bi-functional SuperKines for ImmunoTherapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition --...
Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting
April 08, 2022 09:10 ET
|
Medicenna Therapeutics Corp.
-- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor -- Fc-MDNA413 inhibits in vivo tumor...
Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 10, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company,...
Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting
March 09, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor
March 03, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of...
Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights
February 09, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 -- Preliminary pharmacodynamic data show preferential...
Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022
February 02, 2022 07:30 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Announces Formation of its Scientific Advisory Board
January 31, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer
January 26, 2022 07:00 ET
|
Medicenna Therapeutics Corp.
-- MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated...